Ocular Therapeutix Inc. (OCUL) Financial Statements (2025 and earlier)
Company Profile
Business Address |
15 CROSBY DRIVE BEDFORD, MA 01730 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 195,807 | 102,300 | 164,164 | 228,057 | 54,437 | 54,062 | |||
Cash and cash equivalent | 195,807 | 102,300 | 164,164 | 228,057 | 54,437 | 54,062 | |||
Restricted cash and investments | 150 | ||||||||
Receivables | 26,179 | 21,325 | 21,135 | 12,252 | 2,548 | 201 | |||
Inventory, net of allowances, customer advances and progress billings | 2,305 | 1,974 | 1,250 | 1,201 | 954 | 217 | |||
Inventory | 2,305 | 1,974 | 1,250 | 1,201 | 954 | 217 | |||
Other undisclosed current assets | 7,794 | 4,028 | 4,751 | 4,650 | 2,231 | 1,713 | |||
Total current assets: | 232,235 | 129,627 | 191,300 | 246,160 | 60,170 | 56,193 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 6,472 | 8,042 | 4,867 | 5,844 | 6,655 | ✕ | |||
Property, plant and equipment | 11,739 | 9,856 | 6,956 | 8,095 | 10,151 | 10,236 | |||
Restricted cash and investments | 1,614 | 1,764 | 1,764 | 1,764 | 1,764 | 6,614 | |||
Total noncurrent assets: | 19,825 | 19,662 | 13,587 | 15,703 | 18,570 | 16,850 | |||
TOTAL ASSETS: | 252,060 | 149,289 | 204,887 | 261,863 | 78,740 | 73,043 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 33,055 | 29,220 | 24,713 | 17,016 | 10,903 | 9,159 | |||
Accounts payable | 4,389 | 5,123 | 4,592 | 2,709 | 3,268 | 2,965 | |||
Accrued liabilities | 28,666 | 24,097 | 20,121 | 14,307 | 7,635 | 6,194 | |||
Deferred revenue | 255 | 576 | ✕ | ||||||
Debt | 8,290 | 1,126 | |||||||
Other undisclosed current liabilities | 1,586 | 1,599 | 1,624 | 1,358 | |||||
Total current liabilities: | 34,896 | 31,395 | 26,337 | 26,664 | 12,029 | 9,159 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 74,925 | 54,006 | 57,359 | 48,791 | 58,217 | 24,788 | |||
Long-term debt, excluding current maturities | 74,925 | 54,006 | 51,435 | 41,243 | 49,312 | 24,788 | |||
Liabilities, other than long-term debt | 51,108 | 28,509 | 33,192 | 110,313 | 12,124 | 3,221 | |||
Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 3,221 | ||
Deferred revenue | 14,135 | 13,387 | 13,000 | 12,000 | ✕ | ||||
Other liabilities | 108 | 93 | |||||||
Operating lease, liability | 6,878 | 8,678 | 5,924 | 7,548 | 8,905 | ✕ | |||
Derivative instruments and hedges, liabilities | 29,987 | 6,351 | 20,192 | 98,313 | 12,124 | ||||
Total noncurrent liabilities: | 126,033 | 82,515 | 90,551 | 159,104 | 70,341 | 28,009 | |||
Total liabilities: | 160,929 | 113,910 | 116,888 | 185,768 | 82,370 | 37,168 | |||
Equity | |||||||||
Equity, attributable to parent | 91,131 | 35,379 | 87,999 | 76,095 | (3,630) | 35,875 | |||
Common stock | 12 | 8 | 8 | 8 | 5 | 4 | |||
Additional paid in capital | 788,697 | 652,213 | 633,795 | 615,338 | 379,980 | 333,114 | |||
Accumulated deficit | (697,578) | (616,842) | (545,804) | (539,251) | (383,615) | (297,243) | |||
Total equity: | 91,131 | 35,379 | 87,999 | 76,095 | (3,630) | 35,875 | |||
TOTAL LIABILITIES AND EQUITY: | 252,060 | 149,289 | 204,887 | 261,863 | 78,740 | 73,043 |
Income Statement (P&L) ($ in thousands)
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 58,443 | 51,494 | 43,522 | 17,403 | 4,227 | 1,990 | ||
Cost of revenue | (5,281) | (4,540) | (4,407) | (2,083) | (2,325) | (465) | ||
Cost of product and service sold | (5,281) | (4,540) | (4,406) | (2,083) | (2,325) | |||
Gross profit: | 53,162 | 46,954 | 39,115 | 15,320 | 1,902 | 1,525 | ||
Operating expenses | (135,544) | (125,608) | (117,152) | (78,167) | (87,704) | (60,643) | ||
Operating loss: | (82,382) | (78,654) | (78,037) | (62,847) | (85,802) | (59,118) | ||
Nonoperating income (expense) | 1,646 | 7,616 | 71,484 | (92,789) | (570) | (860) | ||
Investment income, nonoperating | 3,983 | 798 | 33 | 168 | 1,229 | 879 | ||
Interest and debt expense | 14,190 | (7,022) | (6,671) | (6,768) | (6,101) | (1,739) | ||
Loss from continuing operations: | (66,546) | (78,060) | (13,224) | (162,404) | (92,473) | (61,717) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (13,224) | (162,404) | (92,473) | (61,717) | |
Other undisclosed net income (loss) | (14,190) | 7,022 | 6,671 | 6,768 | 178,845 | 1,739 | ||
Net income (loss): | (80,736) | (71,038) | (6,553) | (155,636) | 86,372 | (59,978) | ||
Other undisclosed net loss attributable to parent | (172,744) | |||||||
Net loss available to common stockholders, basic: | (80,736) | (71,038) | (6,553) | (155,636) | (86,372) | (59,978) | ||
Interest on convertible debt | 4,172 | 4,596 | 4,409 | |||||
Dilutive securities, effect on basic earnings per share | 4,502 | (13,841) | (78,121) | |||||
Other undisclosed net loss available to common stockholders, diluted | (14,907) | |||||||
Net loss available to common stockholders, diluted: | (86,969) | (80,283) | (80,265) | (155,636) | (86,372) | (59,978) |
Comprehensive Income ($ in thousands)
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (80,736) | (71,038) | (6,553) | (155,636) | 86,372 | (59,978) | ||
Comprehensive income (loss): | (80,736) | (71,038) | (6,553) | (155,636) | 86,372 | (59,978) | ||
Other undisclosed comprehensive loss, net of tax, attributable to parent | (172,744) | |||||||
Comprehensive loss, net of tax, attributable to parent: | (80,736) | (71,038) | (6,553) | (155,636) | (86,372) | (59,978) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.